A 20-year real-world study on drug survival and predictive factors for infliximab discontinuation in Behçet's syndrome.
Infliximab (IFX) is an immunosuppressive drug widely used for the treatment of patients with Behçet's syndrome (BS) with severe or refractory organ involvements. The aim of this study was to evaluate IFX survival, clinical response and safety profile in a monocentric cohort…